Cefixime overdosage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Cefixime}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUPRAX (CEFIXIME) TABLET SUPRAX (CEFIXIME) CAPSULE ...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Overdosage== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUPRAX (CEFIXIME) TABLET SUPRAX (CEFIXIME) CAPSULE SUPRAX (CEFIXIME) TABLET, CHEWABLE SUPRAX (CEFIXIME) POWDER, FOR SUSPENSION [LUPIN PHARMA] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2 |publisher = | date = | accessdate = }}</ref> | Gastric lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of cefixime did not differ from the profile seen in patients treated at the recommended doses.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUPRAX (CEFIXIME) TABLET SUPRAX (CEFIXIME) CAPSULE SUPRAX (CEFIXIME) TABLET, CHEWABLE SUPRAX (CEFIXIME) POWDER, FOR SUSPENSION [LUPIN PHARMA] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2 |publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 20:41, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overdosage
Gastric lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of cefixime did not differ from the profile seen in patients treated at the recommended doses.[1]
References
Adapted from the FDA Package Insert.